- S&P 500 Futures stays mildly, up for the fourth day in a row.
- US-China tussle, mixed clues on virus and vaccine probe earlier risk-on mood.
- US stimulus, Brexit headlines confuse markets amid a light calendar.
- US NFP awaited, risk news to keep the driver’s seat.
S&P 500 Futures gains eight points, or 0.22% intraday, to 3,672.50 during the initial hour of Tokyo trading. In doing so, the risk barometer nears the record high of 3,681.62 marked the previous day.
Chatters concerning the US coronavirus (COVID-19) stimulus package and the covid vaccine optimism have helped the US equity derivative to refresh the all-time high on Thursday. However, following the rejection of the covid aid package by US Senate Majority Leader Mitch McConnell joins the news of the Pfizer-BioNTech duo’s supply challenge to probe the risks.
Also on the negative side were the updates that the US confirms four companies blacklisted due to the possible links with the Chinese military. Additionally, the US slashing of China's Communist Party members’ visas from 10 years to 1 month and US Director of National Intelligence John Ratcliffe’s tough stand on Beijing also dim the previous optimism.
On the positive side is the news that the US Department of Justice is in talks with the Huawei Finance Chief Meng Wanzhou to allow her to return to China if she agrees to some wrongdoing. Further, CNN’s comments that US President-elect Joe Biden has a slightly constructive view over the Sino-American tussle also keep the risks positive.
Though, fears that the covid numbers from the US are rising by leaps and bounds as well as expectations of a no-deal Brexit challenge the market’s trading sentiment.
As a result, stocks in Asia-Pacific trade mixed while the US 10-year Treasury yields drop 1.1 basis points (bps) to 0.91% by press time.
While fresh news concerning the aforementioned risk catalysts can keep entertaining the global market players, November’s employment report for the US will also be the key to watch amid broad US dollar weakness.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.